Serabelisib

DRUG4 trials

Sponsors

Petra Pharma, Faeth Therapeutics

Conditions

Advanced Solid TumorBreast CancerColo-rectal CancerEndometrial CancerHR+ HER2- Breast CancerHead and Neck CancerLung CancerPIK3CA Mutation

Phase 1

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra PharmaBreast Cancer, Colo-rectal Cancer, Endometrial Cancer +2

Start: 2020-09-01End: 2021-12-30Target: 60Updated: 2020-05-21

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

TerminatedNCT05300048

Faeth TherapeuticsAdvanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation

Start: 2022-04-22End: 2025-04-30Updated: 2026-04-30

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

RecruitingNCT07558733

Faeth TherapeuticsHR+ HER2- Breast Cancer

Start: 2026-04-01End: 2033-05-01Target: 32Updated: 2026-04-30

Phase 2

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

RecruitingNCT06463028

Faeth TherapeuticsEndometrial Cancer

Start: 2024-12-12End: 2029-09-30Target: 40Updated: 2025-12-24

Related Papers

Sapanisertib and serabelisib (PIKTOR) with paclitaxel and a diet substudy in patients with advanced/recurrent endometrial cancer (GOG-3111).

Journal of Clinical Oncology2025-05-28

Researchers Reveal Role of Super-Enhancers in Colorectal Cancer

Oncology Times2022-12-20